Dr. Marty Makary has stepped down as Food and Drug Administration commissioner after weeks of mounting pressure over his handling of regulatory decisions. The agency's top food safety official will assume the role.
Makary's resignation follows internal conflict over his opposition to the Trump administration's decision to approve flavored vapes. Sources indicate he privately voiced disagreement with the vape approval, creating tension between his personal views and the administration's priorities.
The departing commissioner had faced scrutiny since his appointment. Makary built his public profile as a surgeon and medical commentator who frequently questioned government health guidance, particularly during the pandemic. His FDA tenure proved rocky as he navigated balancing independent scientific judgment against political expectations.
The vaping decision appears to have been the breaking point. Makary had reportedly communicated his concerns about approving flavored e-cigarettes privately, but the administration moved forward anyway. Rather than resign in public protest, Makary chose a quieter exit after weeks of pressure mounted.
The FDA oversees regulation of tobacco products, including electronic nicotine delivery systems. Flavored vapes remain contested in public health circles. Researchers have documented that sweet and fruity flavors appeal especially to youth users, driving initiation and dependence. The agency previously restricted flavored combustible cigarettes while allowing menthol, a decision Makary's predecessor had wrestled with extensively.
The leadership transition occurs amid broader shifts in how the Trump administration approaches health regulation. Makary's departure signals tensions between the agency's scientific culture and political directives from above.
His successor as acting commissioner brings deep expertise in food safety and regulatory enforcement. The change raises questions about how the FDA will handle contentious public health issues going forward, particularly those where scientific evidence conflicts with administration preferences.